keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant

keyword
https://www.readbyqxmd.com/read/28324284/nonoperative-management-or-watch-and-wait-for-rectal-cancer-with-complete-clinical-response-after-neoadjuvant-chemoradiotherapy-a-critical-appraisal
#1
Tarik Sammour, Brandee A Price, Kate J Krause, George J Chang
BACKGROUND: There is increasing interest in nonoperative management (NOM) for rectal cancer with complete clinical response (cCR) after neoadjuvant chemoradiation (nCRT). OBJECTIVE: The aim of this systematic review was to summarize the available data on NOM, with the intention of formulating standardized protocols on which to base future investigations. METHODS: A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted...
March 21, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28324267/chemotherapy-induced-irreversible-alopecia-in-early-breast-cancer-patients
#2
Gun Min Kim, Sanghwa Kim, Hyung Seok Park, Jee Ye Kim, Sanggen Nam, Seho Park, Seung Il Kim, DoYoung Kim, Joohyuk Sohn
PURPOSE: The purpose of this work is to determine the prevalence of chemotherapy-induced irreversible alopecia (CIIA), which is defined as an alopecia that exists at least 6 months after completion of chemotherapy and factors affecting CIIA in early breast cancer patients. METHODS: We performed a cross-sectional study. We retrospectively identified breast cancer patients who had received AC (Adriamycin, Cyclophosphamide) or AC-T (AC followed by Taxane) as neoadjuvant or adjuvant chemotherapy...
March 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28319171/a-reported-20-gene-expression-signature-to-predict-lymph-node-positive-disease-at-radical-cystectomy-for-muscle-invasive-bladder-cancer-is-clinically-not-applicable
#3
Kim E M van Kessel, Harmen J G van de Werken, Irene Lurkin, Angelique C J Ziel-van der Made, Ellen C Zwarthoff, Joost L Boormans
BACKGROUND: Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) provides a small but significant survival benefit. Nevertheless, controversies on applying NAC remain because the limited benefit must be weight against chemotherapy-related toxicity and the delay of definitive local treatment. Therefore, there is a clear clinical need for tools to guide treatment decisions on NAC in MIBC. Here, we aimed to validate a previously reported 20-gene expression signature that predicted lymph node-positive disease at radical cystectomy in clinically node-negative MIBC patients, which would be a justification for upfront chemotherapy...
2017: PloS One
https://www.readbyqxmd.com/read/28318082/histopathological-tumour-viability-after-neoadjuvant-chemotherapy-influences-survival-in-resected-pancreatic-cancer-analysis-of-early-outcome-data
#4
Phil Townend, Phil R de Reuver, Terence C Chua, Anubhav Mittal, Stephen J Clark, Nick Pavlakis, Anthony J Gill, Jaswinder S Samra
BACKGROUND: Neoadjuvant therapy is increasingly recognized as an effective strategy prior to pancreatoduodenectomy. We investigate the role of neoadjuvant chemotherapy (NAC) followed by surgery and the predictive role of viable residual tumour cells histopathologically on outcomes. METHODS: The study population comprised of 195 consecutive patients with pancreatic adenocarcinoma who were treated with either NAC or a surgery-first (SF) strategy. Histopathological viable tumour cells were examined in the NAC patients and clinicopathological factors were correlated with overall survival...
March 20, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28317586/strategies-to-improve-local-control-of-resected-pancreas-adenocarcinoma
#5
Paul H Sugarbaker
BACKGROUND: Only approximately one in ten pancreas cancer patients is a candidate for potentially curative resection of this disease. Even this small fraction of patients has a poor prognosis following pancreatico-duodenectomy. The disease has an anatomic location that makes it difficult for the surgeon to maintain adequate margins of resection and prevent tumor spillage at the time of resection. Also, the disease is biologically aggressive and even with a complete visible resection of the disease, micrometastases are likely to remain behind...
March 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28317007/the-role-of-neoadjuvant-chemotherapy-in-the-management-of-patients-with-advanced-stage-ovarian-cancer-survey-results-from-members-of-the-society-of-gynecologic-oncologists-a-5-year-follow-up
#6
Erica Huelsmann, Israel Zighelboim, Amina Ahmed, Summer Dewdney
•NACT use among SGO members for ovarian cancer is explored given recent trials.•Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.•Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.•Very high optimal cytoreduction rates are reported from SGO members.•Despite recent studies, SGO members don't regularly treat patients with NACT/ID.
May 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28316218/-predictive-and-prognostic-significance-of-high-sensitivity-modified-glasgow-prognostic-score-hs-mgps-in-advanced-gastric-cancer-patients-treated-with-neoadjuvant-chemotherapy
#7
Y Cui, J Li, Y H Cao, M Y Liu, Z X Shi, T H Gao
Objective: To study the predictive and prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) on the effect of neoadjuvant chemotherapy for advanced gastric cancer. Methods: 117 patients with advanced gastric cancer received neoadjuvant chemotherapy with SOX (oxaliplatin+ S1) or mFOLFOX 6(oxaliplatin+ CF+ 5-FU) regimen. HS-mGPS was calculated according to blood C-reactive protein (CRP) concentration and serum albumin (ALB) level. The correlation between HS-mGPS and clinicopathological characteristics was determined and the predictors of survival were analyzed...
March 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28316153/-assessment-of-predictive-factors-for-survival-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant-chemoradiotherapy
#8
G J Wu, T Yu, W W Jia, Q An, G Xiao, X Wang
Objective: To evaluate the clinical predictive factors for survival prognosis in patients with locally advanced rectal cancer after neoadjuvant chemoradiotheraphy. Methods: The study included 87 patients with middle and lower locally advanced rectal cancer, who underwent neoadjuvant chemoradiotheraphy followed by radical surgery between April 2007 and May 2015. The clinical factors associated with 3-year disease-free survival (DFS) and overall survival (OS) were analyzed.Kaplan-Meier analysis of disease-free survival and overall survival was performed for all patients...
March 14, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28315155/synchronous-triple-primary-cancers-of-the-pharynx-and-esophagus
#9
Seita Kataoka, Masami Omae, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Yorimasa Yamamoto, Tomohiro Tsuchida, Junko Fujisaki, Kazuhiko Yamada, Masahiro Igarashi
A 72-year-old male with nausea and heartburn was found to have early pharyngeal squamous cell carcinoma, superficial and advanced esophageal squamous cell carcinoma and early esophageal adenocarcinoma by esophagogastroduodenoscopy. Computerized tomography demonstrated left cardiac lymph node swellings. We prioritized the treatment for esophageal squamous cell carcinoma, as this was the most advanced cancer among the triple primaries. The patient underwent neoadjuvant chemotherapy for esophageal squamous cell carcinoma followed by esophagectomy...
March 17, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28315068/efficacy-and-safety-of-nab-paclitaxel-125%C3%A2-mg-m-2-and-nab-paclitaxel-150%C3%A2-mg-m-2-compared-to-paclitaxel-in-early-high-risk-breast-cancer-results-from-the-neoadjuvant-randomized-geparsepto-study-gbg-69
#10
Jenny Furlanetto, Christian Jackisch, Michael Untch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Hermann Wiebringhaus, Sherko Kümmel, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens Uwe Blohmer, Michael Clemens, Serban Dan Costa, Bernd Gerber, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz
PURPOSE: The GeparSepto study demonstrated that the use of nab-paclitaxel instead of paclitaxel prior to anthracycline-based chemotherapy could lead to a significantly increased pCR rate, especially in the triple negative subpopulation. We report efficacy and safety for patients treated with two different doses of nab-paclitaxel in comparison to weekly solvent-formulated paclitaxel. METHODS: Patients were treated for 12 weeks with either intravenous nab-paclitaxel 150 mg/m(2) (nP150) weekly, after study amendment 125 mg/m(2) (nP125) weekly or solvent-based paclitaxel 80 mg/m(2) (P80) weekly followed by epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) on day 1 for four 3-week cycles...
March 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28314992/prognostic-impact-of-normalization-of-serum-tumor-markers-following-neoadjuvant-chemotherapy-in-patients-with-borderline-resectable-pancreatic-carcinoma-with-arterial-contact
#11
Yoshiaki Murakami, Kenichiro Uemura, Takeshi Sudo, Yasushi Hashimoto, Naru Kondo, Naoya Nakagawa, Kenjiro Okada, Shinya Takahashi, Taijiro Sueda
PURPOSE: The survival benefit of neoadjuvant therapy for patients with borderline resectable pancreatic carcinoma has been reported recently. However, prognostic factors for this strategy have not been clearly elucidated. The aim of this study was to clarify prognostic factors for patients with borderline resectable pancreatic carcinoma who received neoadjuvant chemotherapy. METHODS: Medical records of 66 patients with pancreatic carcinoma with arterial contact who intended to undergo tumor resection following neoadjuvant chemotherapy were analyzed retrospectively...
March 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28314842/performance-of-mid-treatment-breast-ultrasound-and-axillary-ultrasound-in-predicting-response-to-neoadjuvant-chemotherapy-by-breast-cancer-subtype
#12
Rosalind P Candelaria, Roland L Bassett, William Fraser Symmans, Maheshwari Ramineni, Stacy L Moulder, Henry M Kuerer, Alastair M Thompson, Wei Tse Yang
BACKGROUND: The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB). METHODS: Patients with invasive breast cancer who underwent neoadjuvant chemotherapy and had pre-treatment and mid-treatment breast and axillary ultrasound were included in this single-institution, retrospective cohort study. Linear regression analysis assessed associations between RCB with (a) change in index breast tumor size, (b) change in index node size, and (c) absolute number of abnormal nodes at mid-treatment...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314323/bevacizumab-combined-with-chemotherapy-in-children-affected-by-hepatocellular-carcinoma-a-single-center-experience
#13
Maria Debora DE Pasquale, Jean de Ville de Goyet, Lidia Monti, Chiara Grimaldi, Alessandro Crocoli, Aurora Castellano
BACKGROUND: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. PATIENTS AND METHODS: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314289/dose-dense-paclitaxel-and-carboplatin-based-neoadjuvant-chemotherapy-followed-by-surgery-or-concurrent-chemo-radiotherapy-in-cervical-cancer-a-preliminary-analysis
#14
Angiolo Gadducci, Cecilia Barsotti, Concetta Laliscia, Stefania Cosio, Antonio Fanucchi, Roberta Tana, Maria Grazia Fabrini
AIM: To assess preliminary results with dose-dense neoadjuvant chemotherapy (NACT) prior to surgery or concurrent chemo-radiotherapy (CCRT) in cervical cancer. PATIENTS AND METHODS: Thirty patients received weekly paclitaxel (80 mg/m(2)) plus carboplatin (AUC2) for 6 cycles followed by radical hysterectomy in 16 (stage Ib2-IIb), conisation in one (stage Ib1), and CCRT in 13 (stage Ib2-IIb). Median follow-up of survivors was 12 months (range=3-22). RESULTS: Among the surgically treated patients, clinical overall response rate (RR) was 82...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28306215/primary-mediastinal-and-retroperitoneal-malignant-germ-cell-tumors-in-children-and-adolescents-results-of-the-tgm95-trial-a-study-of-the-french-society-of-pediatric-oncology-soci%C3%A3-t%C3%A3-fran%C3%A3-aise-des-cancers-de-l-enfant
#15
Hélène Sudour-Bonnange, Cécile Faure-Conter, Hélène Martelli, Frederic Hameury, Brice Fresneau, Daniel Orbach, Cécile Vérité
PURPOSE: To examine the clinical presentation, treatment and results in children and adolescents with primary mediastinal (PM) and retroperitoneal (RP) germ cell tumors (GCTs). METHODS: The TGM95 trial for malignant GCTs was conducted in France between 1995 and 2005 to evaluate a strategy adapted to prognostic factors with cisplatin-based chemotherapy and surgical management. We reviewed patients with TGCTs at PM and RP sites. RESULTS: Among 239 patients, there were 16 patients with PM and 5 with RP tumors, which represent 9% of all patients, highlighting the rarity of these extragonadal locations...
March 17, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28304416/gynecologic-malignancies-in-pregnancy-balancing-fetal-risks-with-oncologic-safety
#16
Christina N Cordeiro, Mary L Gemignani
Importance: Cancer occurs in 0.05% to 0.1% of all pregnancies. Despite literature reporting good oncologic and fetal outcomes in women treated for cancer during pregnancy, as many as 44% of gynecologists would offer termination, and 37% would not administer chemotherapy or radiotherapy in pregnancy. Objectives: The aims of this study were to summarize current recommendations for the treatment of cervical and ovarian cancers in pregnancy and to review updates on existing knowledge regarding the safety of surgical and chemotherapeutic treatments in pregnancy, including both oncologic and fetal outcomes...
March 2017: Obstetrical & Gynecological Survey
https://www.readbyqxmd.com/read/28304150/additional-chemotherapy-and-salvage-surgery-for-poor-response-to-chemoradiotherapy-in-rectal-cancers
#17
Reena Engineer, Vikas Ostwal, Supreeta Arya, Priyamvada Gupta, Supriya Chopra, Prachi Patil, Sudhir Jatal, Avanish Saklani
AIM: A proportion of locally advanced rectal cancer patients who receive neoadjuvant chemoradiotherapy (NACRT) are still unresectable. This study was undertaken to assess the outcomes of giving additional chemotherapy to rectal cancer patients with unresectable disease after NACRT. METHODS: Patients with poor response to NACRT where mesorectal fascia was still involved on MRI and R0 resection was doubtful, received additional four cycles of chemotherapy with either CAPOX or FOLFIRINOX regimen, and the response was reevaluated with MRI and reassessed for surgical resection...
March 17, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28304143/anal-function-after-endoluminal-loco-regional-resection-by-transanal-endoscopic-microsurgery-and-radiotherapy-for-rectal-cancer
#18
Ivano Biviano, Andrea Balla, Danilo Badiali, Silvia Quaresima, Giancarlo D'Ambrosio, Emanuele Lezoche, Enrico Corazziari, Alessandro M Paganini
AIM: In patients with rectal cancer, surgery and chemo-radiotherapy may affect the anal sphincter function. Few studies evaluated the ano-rectal function after neoadjuvant chemo-radiotherapy (n-CRT) and/or Transanal Endoscopic Microsurgery (TEM). The aim of this study was to evaluate the effects of n-CRT and TEM on ano-rectal function. METHOD: Thirty-seven patients with rectal cancer underwent ano-rectal manometry and Wexner score for faecal incontinence at baseline, after n-CRT (cT2-T3N0 cancer) and at 4 and 12 months after surgery...
March 17, 2017: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/28303419/esophagectomy-for-cancer-in-octogenarians-should-we-do-it
#19
Elizabeth Paulus, Caroline Ripat, Vadim Koshenkov, Angela T Prescott, Kiran Sethi, Heather Stuart, Gregory Tiesi, Alan S Livingstone, Danny Yakoub
PURPOSE: Inconsistent data exists regarding esophagectomy outcomes in octogenarians undergoing transhiatal esophagectomy for esophageal cancer. METHODS: A retrospective review was performed for esophagectomy cancer patients between 2000 and 2012 at our tertiary referral center. Outcome data for octogenarians was compared to younger patients aged 20 to 79 years. A case-matched group of patients younger than 80 years old (n = 33) was included based on the Charlson comorbidity index with the octogenarian group (n = 33)...
March 16, 2017: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/28302128/news-from-the-melanoma-sessions-of-the-european-cancer-congress-2017
#20
EDITORIAL
Piotr Rutkowski, Katarzyna Kozak
During the European Cancer Congress, the melanoma sessions focused on practice changing trials. Recent developments and approvals in immunotherapy and targeted agents have significantly changed the landscape of melanoma therapy in the metastatic setting and provide great promise for adjuvant and neoadjuvant treatment in high-risk locoregional disease. Perioperative (combined pre- and postoperative) strategies may be extremely beneficial for patients with bulky stage IIIC disease. The long-term results of the European Organisation for Research and Treatment of Cancer (EORTC) 18071 adjuvant trial ipilimumab versus placebo after complete resection of high-risk stage III melanoma, demonstrating improvement in overall survival, has established the reference bar for further trials with postoperative therapy...
March 17, 2017: BMC Medicine
keyword
keyword
29246
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"